Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is a progressive neurodegenerative disease (ND) and the most prevalent cause of dementia.Acetylcholinesterase (AChE) is the primary cholinesterase responsible for catalyzing the breakdown of acetylcholine and other choline esters that function as neurotransmitters in the body.Given that Alzheimer's disease is a neurological disorder, AChE is thought to play a crucial role in its pathogenesis.On the basis of available literature from neuroprotective plants, a list of 100 secondary metabolites has been compiled.Out of 100 compounds, only forty have drug like properties, and out of these ten, only four satisfy the ADMET criteria.These four are docked against the AChE receptor and validated using redock docking.Kanzonol R (Isoflavonoid) showed significant binding affinity with a binding energy of -10.67 kcal/mol as compared to the redock complex.Kanzonol R has the highest binding affinity and is thus subjected to a complex stability study using molecular dynamics over 100 ns.Kanzonol R outperformed the other compounds and the redock crystal structure in terms of binding affinity and structure stability.The MM-PBSA analysis also shows Kanzonol R and AChE having stable interactions throughout the 100 ns trajectory, and therefore, Kanzonol R may be used as a potent inhibitor of AChE in AD management.
No takes yet. Share an insight, caveat, or question.
Jahan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: